Ten pharmaceutical giants join US research initiative

Government researchers will collaborate with 10 large pharmaceutical companies on a $230 million initiative to speed development of new medications for major diseases, the US National Institutes of Health announced Tuesday.

The five-year initiative targets Alzheimer's Disease, , and lupus, and may be expanded to other ailments, the NIH said.

The goal is to pool resources among NIH and the companies, normally vigorous competitors, to enable analysis of large data sets to track disease progression and the effect of therapies.

Data and early-stage research will be shared and made publicly available, and companies are expected to compete on developing commercial drugs once research passes the preliminary phase.

"Currently, we are investing a great deal of money and time in avenues with high failure rates, while patients and their families wait," said NIH Director Francis Collins.

The challenge "is beyond the scope of any one of us and it's time to work together in new ways to increase our collective odds of success," Collins said.

Taking a drug from early discovery through government approval takes over a decade and 95 percent fail the test. That takes the cost of one success to more than $1 billion, NIH said.

The initiative will be overseen by steering committees led by representatives of NIG and the Food and Drug Administraiton, the private sector companies and patient advocacy groups.

"Our most critical health challenges require new, innovative ways to develop medicines and vaccines," said Rupert Vessey, a at Merck, which is joining the initiative.

"Collaborations such as this, that exchange data, share insights and generate knowledge will be important to unravelling the mysteries of the diseases that cause suffering for individuals and a burden to our society."

The other participating companies are: AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Pfizer, Sanofi and Takeda.

add to favorites email to friend print save as pdf

Related Stories

Deciphering the DNA of Alzheimer's patients

Dec 04, 2013

(HealthDay)—Data that details every gene in the DNA of 410 people with Alzheimer's disease can now be studied by researchers, the U.S. National Institutes of Health announced this week.

Companies back fast Internet-in-schools initiative

Feb 02, 2014

The White House says it's lined up private support for President Barack Obama's pledge to connect 15,000 schools and 20 million students with high-speed Internet service over the next few years.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

7 hours ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.